Antioxidants, redox signaling, and pathophysiology in Schizophrenia: An integrative view

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 2011-2035

  Yao, Jeffrey K ^a,b,c   Keshavan, Matcheri S ^b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ALBUMIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BILIRUBIN; CATALASE; CLOZAPINE; ETHANE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HALOPERIDOL; ISOPROSTANE; LIPID PEROXIDE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTANE; POLYUNSATURATED FATTY ACID; PYRROLIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; URIC ACID;

ANTIOXIDANT ACTIVITY; CHRONIC DISEASE; CIGARETTE SMOKING; DIET; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MEMBRANE DAMAGE; METABOLIC SYNDROME X; NEUROTRANSMISSION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PURINE METABOLISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; BLOOD PROTEINS; CELL MEMBRANE; GLUTATHIONE; HUMANS; INFLAMMATION; LIPID METABOLISM; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 79960858815     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3603     Document Type: Review

References (308)

1. Abdalla DS, Manteiro HP, Olivera JA, and Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 32: 805-807, 1986. (Pubitemid 17028354)
2. Akyol O, Zoroglu S, Armutcu F, Sahin S, and Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18: 377-390, 2004. (Pubitemid 39069754)
3. Al-Chalabi BM, Thanoon IA, and Ahmed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 59: 8-11, 2009.
4. Amminger GP, Schä fer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, and Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebocontrolled trial. Arch Gen Psychiatry 67: 146-154, 2010.
5. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111-112: 1-14, 1998. (Pubitemid 28271929)
6. Arolt A, Rothermund M, Wandinger KP, and Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5: 150-158, 2000. (Pubitemid 30229429)
7. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, and Ma-hadik SP. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53: 56-64, 2003. (Pubitemid 36050936)
8. Awad JA, Morrow JD, Takahashi K, and Roberts II LJ. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem 268: 4161-4169, 1993. (Pubitemid 23072955)
9. Baba H, Suzuki T, Arai H, and Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15: 677-680, 2004. (Pubitemid 38457159)
10. Banks RE. Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls. Crit Rev Clin Lab Sci 37: 131-182, 2000. (Pubitemid 30258831)
11. Bartosz G. Commentary on: free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatry 5: 43-44, 1987.
12. Becker BF. Towards the physiological function of uric acid. Free Radical Biol Med 14: 615-631, 1993. (Pubitemid 23172569)
13. Ben-Shachar D and Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59: 273-296, 2004. (Pubitemid 39752419)
14. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, and McGorry PD. Ethyl-eicosapentaenoic acid in firstepisode psychosis. A 1H-MRS study. Neuropsychopharmacology 33: 2467-2473, 2008.
15. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, and Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebocontrolled trial. Biol Psychiatry 64: 361-368, 2008.
16. Bernstein HG, Heinemann A, Krell D, Dobrowolny H, Bielau H, Keilhoff G, and Bogerts B. Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. Cell Mol Biol (Noisy-le-grand) 51: 279-284, 2005. (Pubitemid 43093379)
17. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, and Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297-302, 1995.
18. Blum-Degen D, Heinemann T, Lan J, Pedersen V, Leblhuber F, Paulus W, Riederer P, and Gerlach M. Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. Brain Res 834: 128-135, 1999. (Pubitemid 29332017)
19. Bockelmann R, Wolf G, Ransmayr P, and Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm 7: 115-121, 1994.
20. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, and Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396, 2008. (Pubitemid 351197614)
21. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, and Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503-1507, 2006. (Pubitemid 44305733)
22. Bredt DS and Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron 8: 3-11, 1992.
23. Brown K, Reid A, White T, Henderson T, Hukin S, Johnstone C, and Glen A. Vitamin E, lipids, lipid peroxidation products and tardive dyskinesia. Biol Psychiatry 43: 863-867, 1998. (Pubitemid 28288363)
24. Buchsbaum MS, Neuchterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E, Asarnow R, Potkin S, and Guich S. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by Positron Emission Tomography. Br J Psychiatry 156: 217-227, 1990.
25. Buckman TD, Kling A, Sutphin MS, Steinberg A, and Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 31: 1-14, 1990. (Pubitemid 20049539)
26. Cadet JL and Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosc Biobehav Rev 18: 457-467, 1994.
27. Cadet JL and Lohr JB. Free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatry 5: 40-48, 1987.
28. Calder PC. Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Braz J Med Biol Res 31: 467-490, 1998. (Pubitemid 28223707)
29. Carlsson M and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276, 1990. (Pubitemid 20193457)
30. Carlsson M and Carlsson A. Schizophrenia a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 16: 425-432, 1990.
31. Carpenter WT Jr. and Buchanan RW. Schizophrenia. N Engl J Med 330: 681-690, 1994. (Pubitemid 24066986)
32. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, and Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog Neuro-Psychopharmacol Biol Psychiatry 22: 947-957, 1998. (Pubitemid 128383225)
33. Chan PH and Fishman RA. Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. J Neurochem 35: 1004-1007, 1980. (Pubitemid 11252733)
34. Chan PH, Fishman RA, Longar S, Chen S, and Yu A. Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 63: 227-235, 1985.
35. Chen DC, Xiu MH, Liu H, Zhang BS, Wang Y, Kosten TR, and Zhang XY. Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. J Psychiat Res 44: 1111-1112, 2010.
36. Choi HK, Mount DB, and Reginato AM. Pathogenesis of gout. Ann Intern Med 143: 499-516, 2005. (Pubitemid 41379398)
37. Chow KC. Vitamin E and cigarette smoking-induced oxidative damage. In: Vitamin E in Health and Disease, edited by Packer L and Fuchs J. New York: Marcel Dekker, Inc., 1992, pp. 683-697.
38. Church WH and Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 33: 419-425, 1994.
39. Ciani E, Groneng L, Voltattorni M, Rolseth V, Contestabile A, and Paulsen RE. Inhibition of free radical production or free radical scavenging protects from excitatoxic cell death mediated by gutamate in cultures of cerebellar granule cells. Brain Res 728: 1-6, 1996. (Pubitemid 26254949)
40. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antiodant defences. Ann N Y Acad Sci 738: 8-14, 1994.
41. Cory JG. Purine and pyrimidine nucleotide metabolism. In: Text Book of Biochemistry with Clinical Correlations, edited by Devlin TM.NewYork: JohnWiley& Sons, 1982, pp. 489-528.
42. Coyle JT and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695, 1993. (Pubitemid 23350687)
43. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, and Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49: 205-209, 2004. (Pubitemid 38594573)
44. Dakhale GN, Khanzode SD, Khanzode SS, and Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 182: 494-498, 2005. (Pubitemid 41464630)
45. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, and Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212: 375-380, 1995.
46. Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235: 747-754, 1986. (Pubitemid 16071985)
47. Deicken RF, Calabrese G, Merrin EL, Meyerhoff DJ, Dillon WP, Weine MW, and Fein G. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry 34: 503-510, 1994.
48. Demisch L, Heinz K, Gerbaldo H, and Kirsten R. Increased concentrations of phosphatidylinositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Prostaglandins Leukot. Essent Fatty Acids 46: 47-52, 1992.
49. Dietrich-Muszalska A, and Olas B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets 20: 90-96, 2009.
50. Dietrich-Muszalska A, Olas B, and Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 16: 386-391, 2005. (Pubitemid 41564335)
51. Dietrich-Muszalska A, Olas B, Glowacki R, and Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 59: 1-7, 2009.
52. Dietrich-Muszalska A and Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 10: 27-33, 2009.
53. Do KQ, Cabungcal JH, Frank A, Steullet P, and Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19: 220-230, 2009.
54. Do KQ, Trabesinger AH, Kirsten-Krü ger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, and Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12: 3721-3728, 2000.
55. Doyle CA and Slater P. Application of [3H]L-N(G)-nitroarginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci Lett 202: 49-52, 1995.
56. Droge W, Mihm S, Bockstette M, and Roth S. Effect of reactive oxygen intermediates and antioxidants on proliferation and function of T lymphocytes. Methods Enzymol 234: 135-151, 1994.
57. Droge W. Free radicals in the physiological control of cell function. Pysiol Rev 82: 47-95, 2002. (Pubitemid 34654215)
58. Droge W. The plasma redox state and ageing. Ageing Res Rev 1: 257-278, 2002. (Pubitemid 38340345)
59. du Bois TM, Deng C, and Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 878-888, 2005. (Pubitemid 41080107)
60. Du Y, Chen CP, Tseng CY, Eisenberg Y, and Firestein BL. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55: 463-472, 2007. (Pubitemid 46383176)
61. Endres S, Meydani SN, Ghrobani E, Schindler R, and Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol 54: 599-603, 1993.
62. Ernster L. Lipid peroxidation in biological membranes mechanisms and implications. In: Active Oxygens, Lipid Peroxides, and Antioxidants, edited by Yagi K. New York, NY: CRC Press, 1993, pp. 1-38.
63. Espersen GT, Grunnet N, Lervang HN, Nielsen GL, Thomsen BS, Faarvang KL, et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin Rheumatol 11: 393-395, 1992.
64. Essali MA, Das I, Belleroche J, and Hirsch SR. The platelet phosphoinositide system in schizophrenia: the effects of neuroleptic treatment. Biol Psychiatry 28: 475-487, 1990. (Pubitemid 20298438)
65. Evans DR, Puczkovski PY, Brandsma MJ, Mahadik JS, and Mahadik SP. Elevated plasma lipid peroxides in schizophrenic patients without dementia. Biol Psychiatry 39: 588, 1996.
66. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, and Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 32: 244-252, 2006. (Pubitemid 43670234)
67. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, and Kuschinsky K. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 358: 351-359, 1998. (Pubitemid 28425492)
68. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, and Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 35: 437-442, 2009.
69. Floyd RA. Mitochondrial damage in neurodegenerative disease. In: Free Radicals in Brain Physiology and Disorders, edited by Packer L, Hiramatsu M, and Yoshikawa T. San Diego, CA: Academic Press, 1996, pp. 313-329.
70. Forstermann U, Schmidt HHHW, Pollock J, Sheng H, Mitchell JA, Warner TD, Nakane M, and Murad F. Isoforms of nitric oxide synthase: characterization and purification from different cell types. Biochem Pharmacology 42: 1849-1857, 1991.
71. Frankel EN. Lipid oxidation. Dundee, Scotland: The Oily Press Ltd., 1998.
72. Freedman DS, Williamson DF, Gunter EW, and Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141: 637-644, 1995.
73. Fukagawa NK. Aging: is oxidative stress a marker or is it causal? Proc Soc Exp Biol Med 222: 293-298, 1999. (Pubitemid 129708644)
74. Fukuzako H, Fukuzako T, Takeuchi K, Ohbo Y, Ueyama K, Takigawa M, and Fujimoto T. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. Prog Neuro-Psychopharmacol Biol Psychiatry 20: 629-640, 1996. (Pubitemid 26236134)
75. Gama CS, Salvador M, Andreazza AC, Kapczinski F, and Belmonte-de-Abreu PS. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 30: 512-515, 2006.
76. Ganguili R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, and Rabin BS. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51: 1-10, 1994.
77. Gattaz WF, Schmitt A, and Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16: 1-6, 1995.
78. Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int Rev Neurobiol 52: 275-302, 2002.
79. Gavazza MB and Català A. Protective effect of N-acetylserotonin on the nonenzymatic lipid peroxidation in rat testicular microsomes and mitochondria. J Pineal Res 37: 153-160, 2004. (Pubitemid 39274112)
80. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S, and Heales SJR. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 86: 228-237, 2003. (Pubitemid 36753863)
81. Gerlach M, Blum-Degen D, Lan J, and Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol 80: 239-245, 1999.
82. Gibson RA, McMurchie EJ, Charnok JS, and Kneebone GM. Homeostatic control of membrane fatty acid composition in the rat after dietary lipid treatment. Lipids 19: 942-951, 1984. (Pubitemid 15196500)
83. Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, and Skinner FS. A red cell membrane abnormality in a sub-group of schizophrenic patients: evidence for two diseases. Schizophr Res 12: 53-61, 1994. (Pubitemid 24135495)
84. Golse B, Debray-Ritzen P, Puget K, and Michelson AM. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. Nouv Presse Med 6: 2449, 1977. (Pubitemid 8128255)
85. Gora D, Sandhya M, Shiv G, and Praveen S. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 50: 16-20, 2008.
86. Grima G, Benz B, Parpura V, Cuenod M, and Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 62: 213-224, 2003. (Pubitemid 36773930)
87. Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, and Michel PP. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 109: 1118-1128, 2009.
88. Guliaeva NV, Levshina IP, and Obidin AM. Indices of lipid free-radical oxidation and the antiradical protection of the brain-the neurochemical correlates of the development of the general adaptation syndrome. Zh Vyssh Nerv Deiat 38: 731-737, 1988.
89. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, and Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 104: 16621-16626, 2007. (Pubitemid 350211066)
90. Halliwell B and Gutteridge JMC. Oxygen radicals and the central nervous system. TINS 8: 22-26, 1984.
91. Harman D. Aging and disease: extending functional life span. Ann N Y Acad Sci 786: 321-336, 1996. (Pubitemid 26273176)
92. Harman D. Aging prospects for future increases in the functional life span. Age 17: 119-146, 1996.
93. Hayashi N, Tashiro T, Yammamori H, Takagi K, Morishima Y, Otsubo Y, Sugiura T, Furukawa K, Nitta H, Nakajama N, Suzuki N, and Ito I. Effects of intravenous omega-3 and omega-6 fat emulsion on cytokine production and delayed type hypersensitivity in burned rats receiving total parenteral nutrition. J Parenter Enteral Nutr 22: 363-367, 1998. (Pubitemid 28520512)
94. Heales SJR, Bolanos JP, Stewart VC, Brookes PS, Land JM, and Clark JB. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1410: 215-228, 1999. (Pubitemid 29078606)
95. Hehner SP, Breitkreutz R, Shubinsky G, Unsoeld H, Schulze-Osthoff K, Schmitz ML, and Droge W. Enhancement of t cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. J Immunology 165: 4319-4328, 2000.
96. Herken H, Uz E, Ozyurt H, and Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 52: 289-290, 2001. (Pubitemid 33052518)
97. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, and Spitsin SV. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14: 691-698, 2000. (Pubitemid 30198568)
98. Horrobin DF, Manku MS, Hillman H, Lain A, and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30: 795-805, 1991.
99. Horrobin DF. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. J Orthomo Psychiatr 9: 33-34, 1980. (Pubitemid 10067197)
100. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30: 193-208, 1998. (Pubitemid 28189552)
101. Huang TL, Liou CW, and Lin TK. Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. Psychiatry Res 177: 18-21, 2010.
102. Hughes JR, Hatsukami DK, Mitchell JE, and Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-997, 1986. (Pubitemid 16073948)
103. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, and Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363, 1996. (Pubitemid 26111202)
104. Hyden MR and Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1: 10, 2004.
105. Ignarro LJ, Cirino G, Casini A, and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovascular Pharmacology 34: 879-886, 1999.
106. Iuliano L, Pedersen JZ, Pratico D, Rotilio G, and Violi F. Role of hydroxyl radicals in the activation of human platelets. Eur J Biochem 221: 695-704, 1994. (Pubitemid 24128039)
107. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, and Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 20: 1-97, 1992.
108. James MJ, Gibson RA, and Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71: 343S-348S, 2000. (Pubitemid 30046139)
109. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and per-oxidative tissue injury. Free Radical Biol Med 9: 515-540, 1990. (Pubitemid 120036914)
110. Javitt DC and Laruelle M. Neurochemical theories. In: Text Book of Schizophrenia, edited by Lieberman JA, Stroup TS, and Perkins DO. Washington, DC: The American Psychiatric Publishing, 2006, pp. 85-116.
111. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu R-M, Forman HJ, and Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity, implications for Parkinson's disease. J Biol Chem 275: 26096-26101, 2000.
112. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, and Trevisan M. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 8: 677-681, 1994. (Pubitemid 24276965)
113. Junn E, Lee NL, Ju HR, Han SH, Im JY, Kang HS, Lee TH, Bae YS, Ha KS, Rhee SG, and Choi I. Requirement of hydrogen peroxide generation in TGF-b1 signal transduction in human lung fibroblast cells: involvement of hydrogen peroxide in Ca2 + in TGF-b1-induced IL-6 expression. J Immunology 165: 2190-2197, 2000. (Pubitemid 30643169)
114. Kaddurah-Daouk R, Kristal BS, and Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Ann Rev Pharmacol Toxicol 48: 653-683, 2008. (Pubitemid 351738167)
115. Kaiya H, Horrobin DF, Manku MS, and Fisher NM. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol Psychiatry 30: 357-362, 1991.
116. Kaiya H, Nishida A, Imai A, Nakashima S, and Nozawa Y. Accumulation of diacylglycerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis? Biol Psychiatry 26: 669-676, 1989. (Pubitemid 19270816)
117. Kale A, Joshi S, Naphade N, Sapkale S, Raju MS, Pillai A, Nasrallah H, and Mahadik SP. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr Res 98: 295-301, 2008. (Pubitemid 350245596)
118. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, and Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175: 47-53, 2010.
119. Kane JM and Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19: 287-302, 1993. (Pubitemid 23183149)
120. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, and Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002. (Pubitemid 35386908)
121. Kao H-T, Cawthon RM, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, and Porton B. Rapid telomere erosion in schizophrenia. Mol Psychiatry 13: 118-119, 2008.
122. Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM, Snyder SH, Moore NC, and WQ Sturner. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 27: 275-284, 1996. (Pubitemid 26142651)
123. Keelan J, Allen NJ, Antcliffe D, Pal S, and Duchen MR. Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane. J Neurosci Res 66: 873-884, 2001.
124. Keith SJ, Regier DA, and Rae DS. Schizophrenic disorders. In: Psychiatric Disorders in America, the Epidemiologic Catchment Area Study, edited by Robins LN and Regier D. New York: Free Press, 1991, pp. 33-52.
125. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, and Mattson MP. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 18: 687-697, 1998. (Pubitemid 28041905)
126. Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, and Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo 31P MRS study. Mol Psychiatry 8: 316-323, 2003. (Pubitemid 36712925)
127. Keshaven MS, Pettegrew JW, and Ward R. Are membrane phospholipid changes in schizophrenia familial? Biol Psychiatry 33: 45A, 1993.
128. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, and Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58: 1-10, 2002. (Pubitemid 35287278)
129. Khan NS and Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Transact 25: 418S, 1997. (Pubitemid 27417040)
130. Kharitonov SA, Robbins RA, Yates D, Keatings V, and Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respiratory Critical Care Med 152: 609-612, 1995.
131. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, and Lee CU. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21: 344-348, 2006.
132. Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E, and Bowie CR. Is schizophrenia a syndrome of accelerated aging? Schizophr Bull 34: 1024-1032, 2008.
133. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, and Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler 10: 278-280, 2004. (Pubitemid 38807454)
134. Kovaleva ES, Orlov ON, Tsutsul'kovskia MIA, Vladimirova TV, and Beliaev BS. Lipid peroxidation processes in patients with schizophrenia. Zh Nevropatol Psikiatr 89: 108-110, 1989. (Pubitemid 19150257)
135. Kristal BS, Shurubor YI, Kaddurah-Daouk R, and Matson WR. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358: 159-174, 2007.
136. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, and Matson WR. Purine catabolism: links to mitochondrial respiration and antioxidant defenses? Arch Biochem Biophys 370: 22-33, 1999. (Pubitemid 29476946)
137. Kunz M, Gama CS, Andreazza AC, Salvador M, Cereser KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, and Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1677-1681, 2008.
138. Kutzing MK and Firestein BL. Altered uric acid levels and disease states. J Pharm Exp Therapeutics 324: 1-7, 2007.
139. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuenod M, Buclin T, and Do KQ. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33: 2187-2199, 2008. (Pubitemid 351992093)
140. Lee BH and Kim YK. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 104: 36-43, 2008.
141. Lieberman JA and Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophr Bull 19: 371-429, 1993. (Pubitemid 23183154)
142. Linden J and Rosin DL. Purinergic system. In: Basic Neurochemistry, Molecular, Cellular and Medical Aspects (7th edition), edited by Siegel GJ, Albers RW, Brady ST, and Price DL. Boston: Elsevier, 2006, pp. 303-316.
143. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, and Arendash GW. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim Biophys Acta 1454: 143-152, 1999. (Pubitemid 29322021)
144. Liu F, You SW, Yao LP, Liu HL, Jiao XY, Shi M, Zhao QB, and Ju G. Secondary degeneration reduced by inosine after spinal cord injury in rats. Spinal Cord 44: 421-426, 2006. (Pubitemid 44015137)
145. Lohr JB and Flynn K. Smoking and schizophrenia. Schizophr Res 8: 93-102, 1992.
146. Lohr JB, Kuczenski R, Bracha HS, Moir M, and Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28: 535-539, 1990. (Pubitemid 20298448)
147. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 48: 1097-1106, 1991.
148. Los M, Droge W, Stricker K, Baeuerle PA, and Schulze-Osthoff K. Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur J Immunol 25: 159-165, 1995.
149. MacGregor DG, Higgins MJ, Jones PA, Maxwell WL, Watson MW, Graham DI, and Stone TW. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. Brain Res 727: 133-144, 1996. (Pubitemid 26246822)
150. Mahadik SP, Mukherjee S, Correnti E, Kelkar HS, Wakade CG, Costa RM, and Scheffer R. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naïve patients at the onset of psychosis. Schizophr Res 13: 239-247, 1994. (Pubitemid 24302654)
151. Mahadik SP and Yao JK. Phospholipids in schizophrenia. In: Textbook of Schizophrenia, edited by Lieberman JA, Stroup TS, and Perkins DO. Washington, DC: The American Psychiatric Publishing, Inc., 2006, pp. 117-135.
152. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, and Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 63: 133-142, 1996. (Pubitemid 26276604)
153. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, and Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43: 674-679, 1998. (Pubitemid 28222388)
154. Mahadik SP, Parikh V, and Khan MM. The role of oxidative stress in modulating membrane and phospholipid function in schizophrenia. In: Phospholipid Spectrum Disorders in Psychiatry and Neurology, edited by Peet M, Glen I, and Horrobin D. Carnforth, UK: Marius Press, 2003, pp. 277-288.
155. Mahadik SP, Pillai A, Joshi S, and Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 18: 119-131, 2006. (Pubitemid 43791675)
156. Martins-de-Souza D, Harris LW, Guest PC, and Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 15: 2067-2079, 2011.
157. Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, Fujita Y, and Lyo M. Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 150B: 86-94, 2009.
158. Matsuzawa D and Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 15: 2057-2065, 2011.
159. McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J, and Paterson J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. Brit Med J 317: 784-785, 1998. (Pubitemid 28427229)
160. McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, and Stanford KE. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medication. Schizophr Res 91: 37-50, 2007.
161. Meister A. Mitochondrial changes associated with glutathione deficiency. Biochim Biophys Acta 1271: 35-42, 1995.
162. Meister A. Selective modification of glutathione metabolism. Science 220: 472-477, 1983. (Pubitemid 13114104)
163. Mellsop GW. Schizophrenia and rheumatoid arthritis. Aust N Z J Psychiatry 6: 214, 1972.
164. Messamore E, Hoffman WF, and Yao JK. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr Res 122: 248-256, 2010.
165. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69: 413-419, 2003. (Pubitemid 37464051)
166. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morill-Labrode A, Dinarello CA, and Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 121: 547-555, 1991.
167. Michel PP and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 76: 428-435, 1990. (Pubitemid 20261989)
168. Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, Weijers HG, and Koutsilieri E. Cu, Zn-, and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 111: 1191-1201, 2004. (Pubitemid 39222778)
169. Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, Lecic-Tosevski D, and Spasic MB. Lipid status, antioxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 34: 303-307, 2010.
170. Millward DJ. Protein deficiency, starvation and protein metabolism. Proc Nutr Soc 38: 77-88, 1979.
171. Miquel J, Economos AC, Fleming J, and Johnson JE Jr. Mitochondrial role in cell aging. Exp Gerontol 15: 575-591, 1998.
172. Miyaoka T, Seno H, Itoga M, Iigima M, Inagaki T, and Horiguchi J. Schizophrenia-associated idiopathic unconjuated hyperbilirubinemia (Gilbert's syndrome). J Clin Psychiatry 61: 868-871, 2000.
173. Miyaoka T, Yasukawa R, Yasuda H, Shimizu M, Mizuno S, Sukegawa T, Inagaki T, and Horiguchi J. Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases in patients with psychiatric disorders. Eur Neuropsychopharmacol 15: 249-252, 2005. (Pubitemid 40487726)
174. Moncada S, Palmer RMJ, and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacology Rev 43: 109-142, 1991.
175. Morrow JD, Awad JA, Boss HJ, Blair IA, and LJ Roberts II. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89: 10721-10725, 1992.
176. Mount DB, Kwon CY, and Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am 32: 313-331, 2006. (Pubitemid 43728821)
177. Mukherjee S, Mahadik SP, Scheffer R, Correnti EE, and Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 19: 19-26, 1996. (Pubitemid 26133209)
178. Mü ller N, Riedel M, Ackenheil M, and Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 1: 173-179, 2000.
179. Muller N, Schiller P, and Ackenheil M. Coincidence of schizophrenia and hyperbillrubinemia. Pharmacopsychiatry 24: 225-228, 1991.
180. Mü ller N, Schlesinger BC, Hadjamu M, Riedel M, Schwarz M, Primbs J, Ackenheil M, Wank R, and Gruber R. Cytotoxic gamma/delta cells (g/dCD8+ ) are elevated in unmedicated schizophrenic patients and related to the Blood-Brain Barrier and the HLA allele DPA 02011. Schizophr Res 12: 69-71, 1998.
181. Muraoka S and Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol 93: 284-289, 2003. (Pubitemid 38096107)
182. Murray J, Oquendo CE, Willis JH, Marusich MF, and Capaldi RA. Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stress. Adv Drug Deliv Rev 60: 1497-1503, 2008.
183. Nakamura H. Thioredoxin and its related molecules: update (Pubitemid 40563224)
184. Nakano Y, Yoshimura R, Nakano H, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Ueda N, and Nakamura J. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol 25: 139-144, 2010.
185. Navarro J, Obrador E, Pellicer JA, Aseni M, Vina J, and Estrela JM. Blood glutathione as an index of radiationinduced oxidative stress in mice and humans. Free Radic Biol Med 22: 1203-1209, 1997. (Pubitemid 27171962)
186. Norris PJ, Faull RL, and Emson PC. Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPHdiaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. Mol Brain Res 41: 36-49, 1996. (Pubitemid 26288142)
187. Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, J Masliah J, and Wolf C. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res 169: 91-96, 2009.
188. Oke AF, May L, and Adams RN. Ascorbic acid distribution patterns in human brain. Ann New York Acad Sci 498: 1-12, 1987.
189. Olincy A, Young DA, and Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 42: 1-5, 1997. (Pubitemid 27293529)
190. Olney JW and Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007, 1995.
191. Othmen LB, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, and Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 32: 155-159, 2008.
192. Pacher P, Beckman JS, and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007. (Pubitemid 46217686)
193. Padurariu M, Ciobica A, Dobrin I, and Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479: 317-320, 2010.
194. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, and Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 50: 54-56, 2004. (Pubitemid 38721170)
195. Palmer RMJ, Ashton DS, and Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666, 1988.
196. Papas AM. Determinants of antioxidant status in humans. Lipids 31: S77-S82, 1996.
197. Patel M, Day BJ, Crapo JD, Fridovich I, and McNamara JO. Requirement for superoxide in excitotoxic cell death. Neuron 16: 345-355, 1996. (Pubitemid 26072367)
198. Peet M, Laugharne J, Rangarajan N, and Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Intl Clin Psychopharmacology 8: 151-153, 1993. (Pubitemid 23294920)
199. Peet M, Laugharne JDE, Mellor J, and Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 55: 71-75, 1996. (Pubitemid 26321121)
200. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, and Allen M. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. Arch Gen Psychiatry 48: 563-568, 1991.
201. Pettegrew JW, Keshaven MS, and Minshew NJ. 31P nuclear magnetic resonance spectroscopy: neuro-development and schizophrenia. Schizophr Bull 19: 335-353, 1993.
202. Phillips M, Sabas M, and Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 46: 861-864, 1993. (Pubitemid 23287353)
203. Pillai A, Parikh V, Terry Jr AV, and Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 41: 372-386, 2007. (Pubitemid 46201949)
204. Pillai A, Reddy R, and Yao JK. Oxidative stress in schizophrenia. In: Fatty Acids and Oxidative Stress in Neuropsychiatric Disorders, edited by Reddy R and Yao JK. New York: Nova Biochemical Books, 2007, pp. 29-42.
205. Porton B, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, and Kao H-T. Telomerase levels in schizophrenia: a preliminary study. Schizophr Res 106: 242-247, 2008.
206. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, and Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801-808, 2008. (Pubitemid 351410515)
207. Prilipko LL and Lideman RR. Lipid peroxidation processes as one of the factors modifying neuronal membrane-bound proteins in schizophrenia. Vestn Akad Med Nauk SSSR 1: 33-37, 1982.
208. Prilipko LL. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In: Free Radicals in the Brain, edited by Packer L, Prilipko L, and Christen Y. Berlin: Spinger-Verlag, 1992, pp. 146-152.
209. Provencher SW. LCModel and LCMgui User's Manual. Available at http://s-provenchercom/pages/lcmmanualshtml, 2001.
210. Pryor WA and Stone K. Oxidants in cigarette smoke. Ann N Y Acad Sci 686: 29, 1992.
211. Puri BK, Counsell SJ, Ross BM, Hamilton G, Bustos MG, and Treasaden IH. Evidence from in vivo 31-phosphorus magnetic resonance spectroscopy phosphodiesters that exhaled ethane is a biomarker of cerebral n-3 polyunsaturated fatty acid peroxidation in humans. BMC Psychiatry 8: S2, 2008.
212. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, and Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 33: 1178-1183, 2009.
213. Ramirez J, Garnica R, Boll MC, Montes S, and Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res 68: 357-361, 2004. (Pubitemid 38526156)
214. Rebec GV. Ascorbate: an antioxidant neuroprotectant and extracellular neuromodulator. In: Metals and Oxidative Damage in Neurological Disorders, edited by Connor JR. New York: Plenum Press, 1997, pp. 149-173.
215. Reddy R and Reddy R. Antioxidant therapeutics in schizophrenia. Antioxid Redox Signal 15: 2047-2055, 2011.
216. Reddy R and Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 55: 33-43, 1996. (Pubitemid 26321116)
217. Reddy R, Sahebarao MP, Mukherjee S, and Murthy JN. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry 30: 409-412, 1991.
218. Reddy RD, and Yao JK. Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. Prostaglands Leukot Essent Fatty Acids 69: 385-391, 2003. (Pubitemid 37464047)
219. Reddy RD, Keshavan MS, and Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62: 205-212, 2003. (Pubitemid 36773929)
220. Reddy RD, Keshavan MS, and Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in firstepisode schizophrenia at neuroleptic-naïve baseline. Schizophr Bull 30: 901-911, 2004. (Pubitemid 40469524)
221. Rice-Evans CA. Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Free Radical Damage and Its Control, edited by Rice-Evans CA and Burdon RH. Amsterdam: Elsevier, 1994, pp. 131-153.
222. Roth S and Droge W. Regulation of interlukin-2 production, interleukin 2 mRNA expression and intracellular glutathioine levels in ex vivo derived T lymphocytes by lactate. Eur J Immunol 21: 1933-1937, 1991.
223. Roth S and Droge W. Regulation of T-cell activation and Tcell growth factor (TCGF) production by hydrogen peroxide. Cell Immunol 108: 417-424, 1987. (Pubitemid 17126493)
224. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, and Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 37: 186-193, 1998. (Pubitemid 28256878)
225. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr., and Kaddurah-Daouk R. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1: 101-108, 2005. (Pubitemid 40778831)
226. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, and Kato E. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 26: 241-247, 1978. (Pubitemid 8361291)
227. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, and Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 56: 41-45, 2004. (Pubitemid 38813404)
228. Schwarz MJ, Muller N, Riedel M, and Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56: 483-486, 2001. (Pubitemid 32397883)
229. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, and Hooper DC. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99: 16303-16308, 2002. (Pubitemid 35462790)
230. Scottish Schizophrenia Research Group. Smoking habits and plasma lipid peroxide and vitamin E levels in nevertreated first-episode patients with schizophrenia. Brit J Psychiatry 176: 290-293, 2000.
231. Seaton TA, Jenner P, and Marsden CD, Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. Biochem Pharmacol 52: 1657-1663, 1996. (Pubitemid 26407980)
232. Shigenaga MK, Hagen T, and Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 91: 10771-10778, 1994. (Pubitemid 24349567)
233. Sinet PM, Debray Q, Carmagnol F, Pelicier, Y, Nicole A, and Jerome H. Normal erythrocyte SOD values in two human diseases: schizophrenia and cystic fibrosis. In: Oxy Radicals and Their Scavenger Systems, Cellular and Medical Aspects. Vol. II, edited by Greenwald RA and Cohen G. New York: Elsevier, 1983, pp. 302-304.
234. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, and Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an openlabel pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31: 1493-1499, 2007. (Pubitemid 47302571)
235. Skinner AO, Mahadik SP, and Garver DL. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. Schizophr Res 76: 83-87, 2005. (Pubitemid 40824563)
236. Skosnik PD and Yao JK. From phospholipid and fatty acid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophreniai Prostaglands Leukot Essent Fatty Acids 69: 367-384, 2003. (Pubitemid 37464046)
237. Smith CV. Free radical mechanisms of tissue injury. In: Free RadicalMechanisms of Tissue Injury, edited byMoslenMT and Smith CV. Boca Raton, FL: CRC Press, 1992, pp. 1-22.
238. Soriani M, Pietraforte D, and Minetti M. Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 312: 180-188, 1994. (Pubitemid 24243816)
239. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Lopez-Real AM, and Labandeira-Garcia JL. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol 64: 125-135, 2002. (Pubitemid 34775183)
240. Soyland E, Lea T, Sandstand B, and Drevon A. Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with infammatory skin disease. Eur J Clin Invest 24: 236-242, 1994. (Pubitemid 24204962)
241. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, and Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7: 313-319, 2001. (Pubitemid 33026256)
242. Stanley JA, Williamson PC, Drost DJ, Carr T, Rylett J, Morrison-Stewart S, and Thompson RT. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res 13: 209-215, 1994. (Pubitemid 24302650)
243. Stassen HH, Bridler R, Hagele S, Hergersberg M, Mehmann B, Schinzel A, Weisbrod M, and Scharfetter C. Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet 96: 173-177, 2000. (Pubitemid 30180858)
244. Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, Cuenod M, and Do KQ. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 30: 2547-2558, 2010.
245. Steullet P, Lavoie S, Kraftsik R, Guidi R, Gysin R, Cuenod M, and Do KQ. A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons. Free Radic Biol Med 44: 1042-1054, 2008.
246. Strassnig M, Brar JS, and Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 29: 393-397, 2003. (Pubitemid 37187700)
247. Strauss JS and Carpenter WT Jr. Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry 34: 159-163, 1977. (Pubitemid 8025013)
248. Strazzullo P and Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17: 409-414, 2007.
249. Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, and Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 28: 959-966, 1990.
250. Suzuki E, Nakaki T, Nakamura M, and Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J Psychiatry Neurosci 28: 288-292, 2003. (Pubitemid 37153436)
251. Suzuki K. Chemistry and metabolism of brain lipids. In: Basic Neurochemistry (3rd edition), edited by Siegel GJ, Albers RW, Agranoff BW, and Katzman R. Boston, MA: Little, Brown & Co., 1981, pp. 355-370.
252. Tandon R, Nasrallah HA, and Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 110: 1-23, 2009.
253. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, and Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 35: 401-405, 2004. (Pubitemid 40018180)
254. Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, and Nakajima N. N-3 versus n-6 polyunsaturated fatty acids in critical illness. Nutrition 14: 551-553, 1998. (Pubitemid 28285295)
255. Thorns V, Hansen L, and Masliah E. nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp Neurology 150: 14-20, 1998. (Pubitemid 28146418)
256. Tien AY and Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry 49: 37-46, 1992.
257. Toncev G, Milicic B, Toncev S, and Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9: 221-226, 2002. (Pubitemid 35013907)
258. Torrey EF and Yolken RH. The schizophrenia-rheumatoid arthritis connection, infectious, immune, or both? Brain Behav Immun 15: 401-410, 2001.
259. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, and Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 60: 458-464, 2006. (Pubitemid 44060803)
260. van der Veen RC, Hinton DR, Incardonna F, and Hofman FM. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77: 1-7, 1997. (Pubitemid 27286370)
261. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, and Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res 87: 129-136, 1999. (Pubitemid 29494972)
262. van Os J and Kapur S. Schizophrenia. Lancet 374: 635-645, 2009.
263. Vaughan K and McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust N Z J Psychiatry 33: 84-88, 1999. (Pubitemid 29121904)
264. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, and Shetty K. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164: 1557-1560, 2007. (Pubitemid 350069735)
265. Villemain F, Chate-noud L, Galinowski A, Homo-Delar-che F, Genestet D, Loo H, Zarifarain E, and Bach JF. Aberrant T-cell-mediated immunity in untreated schizophrenic patients: deficient Interleukin-2 production. Am J Psychiatry 146: 609-616, 1989. (Pubitemid 19121282)
266. Vinogradov S, Gottesman II, Moises HW, and Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 17: 669-678, 1991.
267. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, Erel O, Herken H. A defect in the antioxidant defense system in Schizophrenia. Neuropsychobiology 60: 87-93, 2009.
268. Vitek L, Lenicek M, Jirsa M, Novotna M, Novotny L, Eberova J, Petrasek J, and Jirsa M. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res 178: 449-450, 2010.
269. Wang JF, Shao L, Sun X, and Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11: 523-529, 2009.
270. Waring WS, Webb DJ, and Maxwell SR. Uric acid as a risk factor for cardiovascular disease. Quart J Med 93: 707-713, 2000.
271. Wayner DDM, Burton GW, Ingold KU, Barclay LRC, and Locke SJ. The relative contribution of vitamine E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 924: 408-419, 1987.
272. Wilke I, Arolt V, Rothermundt M, Weitzsch CH, Hornberg M, and Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279-284, 1996. (Pubitemid 26252546)
273. Williamson P, Drost D, Stanley J, Carr T, Morrison S, and Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 48: 578, 1991.
274. Wolfler A, Abuja PM, Schauenstein K, and Liebmann PM. N-acetylserotonin is a better extra-and intracellular antioxidant than melatonin. FEBS Lett 449: 206-210, 1999. (Pubitemid 29192907)
275. Wong C-T, Tsoi W-F, and Saha N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 22: 165-171, 1996. (Pubitemid 26394564)
276. Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, McGorry PD, and Pantelis C. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 33: 354-357, 2009.
277. Xing G, Chavko M, Zhang LX, Yang S, and Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58: 21-30, 2002. (Pubitemid 35291183)
278. Yamada K, Kanba S, Anamizu S, Ohnishi K, Ashikari I, Yagi G, and Asai M. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 27: 1223-1225, 1997. (Pubitemid 27401845)
279. Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu SS, Herken H, Savas HA, Koylu A, and Akyol O. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophreniai Neuropsychobiology 47: 61-65, 2003. (Pubitemid 36469841)
280. Yao JK and Cheng P. Determination of multiple redoxactive compounds by high-performance liquid chromatography with coulometric multi-electrode array system. J Chromatogr B 810: 93-100, 2004. (Pubitemid 39195028)
281. Yao JK and Reddy RD. Metabolic investigation in psychiatric disorders. Mol Neurobiology 31: 193-203, 2005. (Pubitemid 41271203)
282. Yao JK and van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 59: 297-326, 2004. (Pubitemid 39753905)
283. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, and Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. Mol Psychiatry 15: 938-953, 2010.
284. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, and Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in firstepisode neuroleptic-naïve patients with schizophrenia. PLoS One 5: e9508, 2010.
285. Yao JK, Leonard S, and Reddy R. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42: 7-17, 2000. (Pubitemid 30116755)
286. Yao JK, Leonard S, and Reddy RD. Altered glutathione redox state in schizophrenia. Disease Markers 22, 83-93, 2006. (Pubitemid 41831607)
287. Yao JK, Leonard S, and Reddy RD. Increased nitric oxide radicals in postmortem brains from schizophrenic patients. Schizophr Bull 30: 923-934, 2004. (Pubitemid 40469526)
288. Yao JK, Reddy R, and van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 45: 1512-1515, 1999. (Pubitemid 29457565)
289. Yao JK, Reddy R, and van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80: 29-39, 1998. (Pubitemid 28370837)
290. Yao JK, Reddy R, McElhinny LG, and van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatry Res 32: 385-391, 1998. (Pubitemid 28491244)
291. Yao JK, Reddy R, McElhinny LG, and van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32: 1-8, 1998. (Pubitemid 28338118)
292. Yao JK, Reddy RD, and van Kammen DP. Abnormal agerelated changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97: 137-151, 2000. (Pubitemid 32126553)
293. Yao JK, Reddy RD, and van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15: 287-310, 2001. (Pubitemid 32337052)
294. Yao JK, Stanley JA, Reddy RD, Keshavan MS, and Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 52: 823-830, 2002.
295. Yao JK, van Kammen DP, and Gurklis J. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Res 60: 11-21, 1996. (Pubitemid 26076966)
296. Yao JK, van Kammen DP, and Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13: 217-226, 1994. (Pubitemid 24302651)
297. Yao JK, van Kammen DP, Reddy RD, and Kelley ME. Superoxide dismutase and negative symptoms in schizophrenia. Biol Psychiatry 43: 123S-124S, 1998.
298. Yao JK, Yasaei P, and van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 46: 39-46, 1992.
299. Yao JK. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In: Phospholipid Spectrum Disorders in Psychiatry and Neurology (2nd edition), edited by Peet M, Glen I, and Horrobin DF. Lancashire, UK: Marius Press, 2003, pp. 193-212.
300. Zhang F and Dryhurst G. Effects of l-cysteine on the oxidative chemistry of dopamine: new reaction pathways of potential relevance to ideopathic Parkinson's disease. J Med Chem 37: 1084-1098, 1994. (Pubitemid 24145369)
301. Zhang XY, Chen DC, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, and Kosten TR. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 113: 151-157, 2009.
302. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, and Zhou DF. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81: 291-300, 2006. (Pubitemid 43107705)
303. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, and Kosten TR. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 68: 754-760, 2007. (Pubitemid 46841859)
304. Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, and Kosten TR. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 32: 2020-2024, 2007. (Pubitemid 47258513)
305. Zhang XY, Zhou DF, Cao LY, Zhang PY, and Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 117: 85-88, 2003. (Pubitemid 36173777)
306. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen DC, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, and Kosten TR. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl) 204: 177-184, 2009.
307. Zhang ZJ, Ramchand CN, Ramchand R, Milner E, Telang SD, and Peet M. Glutathione peroxidase (GSHPx) activity in plasma and fibroblasts from schizophrenics and control. Biol Psychiatry 29: 103-104, 1998.
308. Zoroglu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, and Akyol O. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatry Res 36: 309-315, 2002. (Pubitemid 34764055)